Servier Deal Termination Fails To Dent MacroGenics’ Flotetuzumab Optimism

 
• By Alexandra Shimmings

The French firm has handed back rights to MacroGenics’ lead DART candidate flotetuzumab. Undaunted, MacroGenics is forging ahead with clinical development including in combination use, while the market awaits a filing and license deal for its lead product margetuximab.

Steps
• Source: Shutterstock

More from Business

More from Scrip